Doctors in Bengaluru have emphasized that a new Alzheimer's drug shows the best results when administered in the early stages of the disease. However, they also noted that late diagnosis remains a common problem, with most patients presenting only at moderate or advanced stages of cognitive impairment.
Challenges in Early Detection
According to specialists, many patients in India are diagnosed with Alzheimer's only after significant cognitive decline has occurred. This limits the effectiveness of treatments that are designed to slow disease progression. The new drug, which targets amyloid plaques in the brain, is most beneficial for those with mild symptoms.
Expert Insights
Dr. N. Kumar, a neurologist at a leading Bengaluru hospital, stated: “The window for optimal treatment is narrow. If we can catch Alzheimer's early, this drug can make a meaningful difference in patients' lives.” He urged increased awareness and routine cognitive screenings for older adults.
Another doctor, Dr. Priya Sharma, added: “Late diagnosis is a barrier not just for treatment but also for clinical trials. We need to educate families about early warning signs.”
Public Health Implications
The Alzheimer's Association of India estimates that over 5 million people in the country live with dementia, with Alzheimer's being the most common cause. The new drug, recently approved by the FDA, offers hope but requires a shift in diagnostic practices.
- Early symptoms include memory loss, confusion with time or place, and difficulty completing familiar tasks.
- Doctors recommend annual cognitive assessments for individuals over 65.
- Family history and genetic factors can increase risk.
While the drug is not a cure, it can slow cognitive decline by up to 30% in early-stage patients. However, its high cost and need for regular infusions pose challenges for widespread use in India.
Moving Forward
Medical professionals in Bengaluru are calling for better public health campaigns and training for primary care physicians to identify Alzheimer's early. They also stress the importance of lifestyle interventions, such as diet and exercise, in reducing risk.
As research continues, the hope is that combination therapies and earlier detection will transform outcomes for millions of patients worldwide.
